Transcriptomics Market Incredible Possibilities, Growth with Industry Study, Detailed Analysis by (Roche, HEC Pharm, Shanghai Zhongxisanwei, GlaxoSmithKline) Global Forecast to 2025

This report provides in depth study of “Transcriptomics Market” using SWOT analysis i.e. Strength, Weakness, Opportunities and Threat to the organization. The Transcriptomics Market report also provides an in-depth survey of key players in the market organization.

Global Transcriptomics Market overview:

BusinessIndustryReports have new report spread across 96 pages is an overview of the Global Transcriptomics Market Report 2020. The Global Transcriptomics Market is projected to grow at a healthy growth rate from 2020 to 2024 according to new research. The study focuses on market trends, leading players, supply chain trends, technological innovations, key developments, and future strategies.

Available Exclusive Sample Copy of this Report @ https://www.businessindustryreports.com/sample-request/263478

The transcriptomics market has witnessed significant growth in the past few years mainly due to the increasing technological advancements in the field of ‘omics’ research and application of sequencing technologies in RNA Analysis research. Similarly, the increasing government and private funding for research coupled with research and development investments by the biotechnology companies are expected to drive the transcriptomics market. Similarly, the application of RNA Analysis in the field of biomarker discovery opens new growth avenues with the rising preference of personalized medicine across the globe. However, the higher investment costs that restrict the adoption of RNA Analysis products and dearth of skilled professionals are the factors hampering the growth of this market to a certain extent.

The Global Transcriptomics Market is segmented on the basis of Product Type, Application, End Use Industry and Region. On the Basis of Product Type segment, the Transcriptomics Market is sub segmented into PCR, Microarray, Sequencing, Sequencing type proportion is 45.4% at most. Based on End Use Industry segment, the Transcriptomics Market is sub segmented into Pharmaceutical and Biotechnology, Academic Research and Government Institutes, Hospitals and Diagnostic Centers, Academic research and government agencies use it the most.

The Asia-Pacific region is projected to register a highest growth in the market between 2020 and 2024. The growing end-user industry is the key driver of the market in the region. Europe is projected to witness a slow growth during the forecast period due to stringent environment norms in the region. North America is the largest market for Transcriptomics followed by Asia-Pacific. The increasing demand from the water treatment segment coupled with the rising demand from reviving Technology industry is driving the market for Transcriptomics in North America.

Some of the Transcriptomics Market manufacturers involved in the market are Roche, HEC Pharm, Shanghai Zhongxisanwei, GlaxoSmithKline, Guangzhou Pharmaceutical, Hunan Nucien Pharmaceutical, Acquisitions and effective mergers are some of the strategies adopted by the Transcriptomics Market manufacturers. New product launches and continuous technological innovations are the Transcriptomics Market strategies adopted by the major players.

Latest Industry Updates:

Roche :today announced that the European Commission has approved Venclyxto® (venetoclax) in combination with Gazyvaro® (obinutuzumab) for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).

“Venclyxto plus Gazyvaro is the first fixed-duration, chemotherapy-free treatment option that has been shown to help patients with untreated chronic lymphocytic leukaemia live longer without their disease progressing,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “This is an important step forward for adults with this disease in the EU, who will now have an effective treatment option that enables them to end treatment after one year.”

The approval is based on results from the primary analysis of the pivotal phase III CLL14 study, which evaluated the combination of 12-month, fixed-duration Venclyxto plus Gazyvaro compared to Gazyvaro plus chlorambucil in adults with previously untreated CLL who had co-existing medical conditions. Results from the primary analysis showed that the combination of Venclyxto plus Gazyvaro led to a 65% reduction in the risk of disease worsening or death (progression-free survival [PFS], as assessed by investigators) compared to Gazyvaro plus chlorambucil, a current standard-of-care for CLL (HR=0.35; 95% CI 0.23-0.53; p

About us

BusinessindustryReports.com is digital database of comprehensive market reports for global industries. As a market research company, we take pride in equipping our clients with insights and data that holds the power to truly make a difference to their business. Our mission is singular and well-defined – we want to help our clients envisage their business environment so that they are able to make informed, strategic and therefore successful decisions for themselves.

Media Contact

Business Industry Reports

Pune – India

sales@businessindustryreports.com

+19376349940

This release was published on openPR.